IMPORTANT SHAREHOLDER ALERT: Goldberg Law PC Files Securities Class Action Lawsuit Against INSYS Therapeutics, Inc. and Strongly Encourages Investors to Contact the Firm

LOS ANGELES--()--Goldberg Law PC (www.Goldberglawpc.com) announces that it has filed a class action lawsuit against INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (Nasdaq: INSY). The class action, filed in the United States District Court, District of Arizona, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired shares between March 3, 2015 and January 25, 2016, inclusive (the “Class Period”). Investors who suffered losses are encouraged to contact the Firm in advance of the April 4, 2016, lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 708, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Insys is a specialty pharmaceutical company that focuses on the development and marketing of supportive care products for patients suffering from chronic pain. Insys’s core product, Subsys, is a sublingual fentanyl spray designed to treat breakthrough cancer pain (“BTCP”) in opioid-tolerant patients.

According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (i) the Company was engaged in the illegal and improper off-labeling marketing of Subsys; (ii) certain Insys employees—including Defendant Michael L. Babich, the President and Chief Executive Officer of Insys during much of the Class Period—were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (iii) as a result, the Company’s financial statements were materially false and misleading at all relevant times.

On January 25, 2016, the Southern Investigating Report Foundation (“SIRF”) published an article alleging that the Company pressured employees to create novel plots to promote the illegal use and sale of Subsys. The article follows a June 25, 2015 New York Times article that covered the guilty conviction of a Connecticut nurse who accepted more than $83,000 in kickbacks from Insys as payment for writing $1 million worth of Subsys prescriptions.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, via email at info@goldberglawpc.com, or visit our website at Goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq. 800-977-7401
Brian Schall, Esq. 800-977-7401
info@goldberglawpc.com
Goldberglawpc.com

Contacts

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq. 800-977-7401
Brian Schall, Esq. 800-977-7401
info@goldberglawpc.com
Goldberglawpc.com